Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.96 USD | +1.78% | +2.98% | +25.38% |
Sales 2024 * | 4.62M 6.32M | Sales 2025 * | 3.63M 4.96M | Capitalization | 6.13B 8.38B |
---|---|---|---|---|---|
Net income 2024 * | -516M -705M | Net income 2025 * | -562M -768M | EV / Sales 2024 * | 1,024 x |
Net cash position 2024 * | 1.4B 1.91B | Net cash position 2025 * | 866M 1.18B | EV / Sales 2025 * | 1,451 x |
P/E ratio 2024 * |
-11.3
x | P/E ratio 2025 * |
-10.5
x | Employees | 378 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.88% |
Latest transcript on Revolution Medicines, Inc.
1 day | +1.78% | ||
1 week | +2.98% | ||
Current month | +11.57% | ||
1 month | +19.87% | ||
3 months | +29.59% | ||
6 months | +80.61% | ||
Current year | +25.38% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Goldsmith
CEO | Chief Executive Officer | 62 | 14-09-30 |
Jack Anders
DFI | Director of Finance/CFO | 47 | 18-07-31 |
Wally Reiher
CTO | Chief Tech/Sci/R&D Officer | - | 15-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Goldsmith
CEO | Chief Executive Officer | 62 | 14-09-30 |
Alexis Borisy
BRD | Director/Board Member | 52 | 14-10-31 |
Sandra Horning
BRD | Director/Board Member | 75 | 11-08 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.16% | 0 M€ | 0.00% | - | |
0.12% | 0 M€ | 0.00% | - | |
0.05% | 773 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 35.96 | +1.78% | 1,213,741 |
24-04-25 | 35.33 | -0.73% | 1,192,512 |
24-04-24 | 35.59 | -1.85% | 1,283,498 |
24-04-23 | 36.26 | -0.47% | 1,366,415 |
24-04-22 | 36.43 | +4.32% | 916,323 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.38% | 6.13B | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- RVMD Stock